| Atypical antipsychotic drugs and the risk of sudden cardiac death WA Ray, CP Chung, KT Murray, K Hall, CM Stein New England journal of medicine 360 (3), 225-235, 2009 | 1479 | 2009 |
| Azithromycin and the risk of cardiovascular death WA Ray, KT Murray, K Hall, PG Arbogast, CM Stein New England Journal of Medicine 366 (20), 1881-1890, 2012 | 1227 | 2012 |
| Premature coronary-artery atherosclerosis in systemic lupus erythematosus Y Asanuma, A Oeser, AK Shintani, E Turner, N Olsen, S Fazio, ... New England Journal of Medicine 349 (25), 2407-2415, 2003 | 1084 | 2003 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update SA Scott, K Sangkuhl, CM Stein, JS Hulot, JL Mega, DM Roden, TE Klein, ... Clinical Pharmacology & Therapeutics 94 (3), 317-323, 2013 | 1040 | 2013 |
| New drugs for rheumatoid arthritis NJ Olsen, CM Stein New England Journal of Medicine 350 (21), 2167-2179, 2004 | 990 | 2004 |
| Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing MV Relling, EE Gardner, WJ Sandborn, K Schmiegelow, CH Pui, SW Yee, ... Clinical Pharmacology & Therapeutics 89 (3), 387-391, 2011 | 887 | 2011 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing JA Johnson, L Gong, M Whirl‐Carrillo, BF Gage, SA Scott, CM Stein, ... Clinical Pharmacology & Therapeutics 90 (4), 625-629, 2011 | 774 | 2011 |
| Genetic determinants of response to warfarin during initial anticoagulation UI Schwarz, MD Ritchie, Y Bradford, C Li, SM Dudek, A Frye-Anderson, ... New England Journal of Medicine 358 (10), 999-1008, 2008 | 772 | 2008 |
| Molecular basis of ethnic differences in drug disposition and response HG Xie, RB Kim, AJJ Wood, CM Stein Annual review of pharmacology and toxicology 41 (1), 815-850, 2001 | 770 | 2001 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing KA Birdwell, B Decker, JM Barbarino, JF Peterson, CM Stein, W Sadee, ... Clinical Pharmacology & Therapeutics 98 (1), 19-24, 2015 | 698 | 2015 |
| COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease WA Ray, CM Stein, JR Daugherty, K Hall, PG Arbogast, MR Griffin The Lancet 360 (9339), 1071-1073, 2002 | 688 | 2002 |
| Oral erythromycin and the risk of sudden death from cardiac causes WA Ray, KT Murray, S Meredith, SS Narasimhulu, K Hall, CM Stein New England Journal of Medicine 351 (11), 1089-1096, 2004 | 667 | 2004 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics‐guided warfarin dosing: 2017 update JA Johnson, KE Caudle, L Gong, M Whirl‐Carrillo, CM Stein, SA Scott, ... Clinical Pharmacology & Therapeutics 102 (3), 397-404, 2017 | 641 | 2017 |
| ACCF/AHA clopidogrel clinical alert: approaches to the FDA “Boxed Warning” a report of the american college of cardiology foundation task force on clinical expert consensus … Writing Committee Members, DR Holmes Jr, GJ Dehmer, S Kaul, D Leifer, ... Circulation 122 (5), 537-557, 2010 | 637 | 2010 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy SA Scott, K Sangkuhl, EE Gardner, CM Stein, JS Hulot, JA Johnson, ... Clinical Pharmacology & Therapeutics 90 (2), 328-332, 2011 | 581 | 2011 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update MV Relling, M Schwab, M Whirl‐Carrillo, G Suarez‐Kurtz, CH Pui, ... Clinical Pharmacology & Therapeutics 105 (5), 1095-1105, 2019 | 566 | 2019 |
| A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose GM Cooper, JA Johnson, TY Langaee, H Feng, IB Stanaway, UI Schwarz, ... Blood, The Journal of the American Society of Hematology 112 (4), 1022-1027, 2008 | 538 | 2008 |
| ADHD drugs and serious cardiovascular events in children and young adults WO Cooper, LA Habel, CM Sox, KA Chan, PG Arbogast, TC Cheetham, ... New England Journal of Medicine 365 (20), 1896-1904, 2011 | 531 | 2011 |
| Inhibition of P-glycoprotein–mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine MF Fromm, RB Kim, CM Stein, GR Wilkinson, DM Roden Circulation 99 (4), 552-557, 1999 | 530 | 1999 |
| Increased coronary‐artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors CP Chung, A Oeser, P Raggi, T Gebretsadik, AK Shintani, T Sokka, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2005 | 508 | 2005 |
